Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Geographic Atrophy Market Growth Performance Trended Historically, And What Lies Ahead?

There has been significant growth in the size of the geographic atrophy market in the recent past. The market size is projected to increase from $1.86 billion in 2024 to $2.11 billion in 2025, reflecting a compound annual growth rate (CAGR) of 13.7%. Factors contributing to the growth during the historic period include an aging population, an increased demand for effective treatment methods, a higher prevalence of geographic atrophy, greater health consciousness, and a rise in instances of retinal diseases.

Predictions indicate a swift expansion in the size of the geographic atrophy market in the approaching years, reaching a noteworthy$3.47 billion in 2029″ with a compound annual growth rate (CAGR) of 13.2%. This progression during the forecasted span is primarily due to the enhanced emphasis on research and development activities, amplified disbursement in R&D, swelling usage of smartphones, escalating healthcare spending, and boosted investments in clinical trials. The forthcoming period is likely to witness trends such as progress in gene therapy, innovations in healthcare technology, new technology development, the surge in telemedicine adoption, and the introduction of innovative and effective pharmaceuticals.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21984&type=smp

What Are the Major Market Drivers Behind the Rising Adoption of Geographic Atrophy Market?

The expected growth of the geographic atrophy market is linked to the rising prevalence of age-related macular degeneration. This eye condition, predominant in older adults, damages the retina’s central part, causing problems with seeing fine details. The increase in AMD cases is largely due to a growing aging population who experience gradual eye damage due to natural aging processes. This makes them increasingly susceptible to the disease. Treatments for geographic atrophy help manage AMD by slowing retinal damage progression and preserving the remaining vision. As per a Medical News Today report in January 2024, an American digital media firm, the worldwide cases of AMD are predicted to increase from 196 million to 288 million by 2040. Thus, the burgeoning prevalence of AMD is influencing the geographic atrophy market’s growth.

Which Key Market Segments Comprise the Geographic Atrophy Market and Drive Its Revenue Growth?

The geographic atrophymarket covered in this report is segmented –

1) By Drug Type: Anti-Vascular Endothelial Growth Factor (VEGF) Therapy; Complement Inhibitors; Neuroprotective Agents; Other Drugs

2) By Diagnosis: Fundus Autofluorescence (FAF); Optical Coherence Tomography Angiography (OCT-A); Multifocal Electroretinography (mfERG)

3) By Route Of Administration: Intravitreal; Oral; Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Other Distribution Channels

Subsegments:

1) By Anti-Vascular Endothelial Growth Factor (VEGF) Therapy: Ranibizumab; Aflibercept; Bevacizumab

2) By Complement Inhibitors: Pegcetacoplan; Lfg316

3) By Neuroprotective Agents: Latanoprost; Brimonidine

4) By Other Drugs: Steroids; Retinoids; Combination Therapy

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=21984&type=smp

Which Areas Are Leading Regions in the Geographic Atrophy Market Expansion Across the Globe?

North America was the largest region in the geographic atrophy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the geographic atrophy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Strategic Trends Steering theGeographic Atrophy Market Direction?

Innovation focused strategies are being employed by significant firms in the geographic atrophy market, such as complement inhibitor therapy, for the advancement of treatment measures for the condition. This therapy is a treatment method that decelerates an excessively reactive immune response, often linked with certain diseases, and plays a crucial role in safeguarding healthy cells from damage, thereby slowing down the progression of the disease. For example, Astellas Pharma Inc., a pharmaceutical organization based in Japan, secured the Food and Drug Administration approval for IZERVAY (avacincaptad pegol intravitreal solution) for geographic atrophy in February 2025. This US-based government agency’s endorsement of IZERVAY removed dosing duration restrictions, thus providing a new treatment pathway for geographic atrophy (GA) caused by age-related macular degeneration (AMD). This step further provides increased flexibility in managing GA and provides extended treatment possibilities for both patients and healthcare providers.

View the full report here:

https://www.thebusinessresearchcompany.com/report/geographic-atrophy-global-market-report

How Is the Geographic Atrophy Market Conceptually Defined?

Geographic atrophy is an eye condition that causes gradual vision loss due to damage in the retina. It is a severe form of age-related macular degeneration (AMD) that leads to blind spots in central vision.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21984

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model